Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

This study found that pelage abnormalities in Harlequin mutant mice are linked to severe AIF deficiency and associated with altered expression of genes related to hair structure.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study demonstrated that AtVLN4 plays a role in root hair growth by regulating actin organization in a calcium-dependent manner.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This study found that platelet factor 4 in platelet-rich plasma suppresses human hair follicle growth and alters related gene expressions, suggesting potential implications for its use in hair loss treatment.

Reducing SFRP1 can promote hair growth and may help treat hair loss.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

In human hair follicle keratinocytes, this study found that treatment with the pharmacological inhibitor QLT0267 led to a strong inhibition of proliferation and migration and induced nearly 100% apoptosis.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This study suggests that Artemis, particularly phosphorylated at serine 516, may have roles in hair follicle growth by influencing differentiation, proliferation, apoptosis, and cell cycling.

This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study suggests that impaired VDR signaling in mice leads to dysregulated Ddit4 expression, impacting hair cycle progression and wound healing.

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, challenging the traditional belief that the disease is primarily driven by CD8+ T cells.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study found that Ift20 is essential for hair follicle stem cell identity and hair regrowth, and it regulates keratinocyte migration during wound healing through focal adhesion integrin recycling, independently of ciliogenesis.

This review suggests that excessive facial photoprotection could play a role in frontal fibrosing alopecia through a disturbance in immunological balance via the aryl hydrocarbon receptor-kynurenine pathway.

This study identified a mutant in Arabidopsis with shorter root hairs due to early growth cessation, implicating the IRE gene in regulating root hair growth duration.